DOJ Cannabis Rescheduling Could Reignite Banking Interest as Tax Clarity Emerges

The U.S. Department of Justice’s decision to move state-licensed medical cannabis products to Schedule III is already reshaping expectations across the financial sector. While the policy stops short of full legalization, early signals suggest it could reopen conversations between cannabis operators and financial institutions that have largely stayed on the sidelines.

According to a recent report by American Banker, the move could reignite interest from banks and credit unions as perceived federal risk declines.

The change goes beyond classification—it alters how capital, compliance, and institutional participation interact with the sector. For years, cannabis businesses have operated in a fragmented system that has limited access to banking, capital, and institutional participation. That framework may now begin to shift.

Banking Interest Returns?

The immediate effect of rescheduling is not a full green light for banking, but a recalibration of risk.

As federal classification moves away from Schedule I, financial institutions may become more willing to engage with compliant cannabis operators, particularly in the medical segment. Reduced legal ambiguity can expand the scope of services offered, from basic deposit accounts to more advanced financial products.

However, the change introduces new layers of oversight.

Cannabis businesses operating under Schedule III will still be subject to federal compliance expectations, including anti-money laundering controls and regulatory coordination across agencies. For banks, this means opportunity paired with continued diligence.

Treasury Signals Tax Relief as 280E Pressure Eases

One of the most immediate and measurable impacts of rescheduling is tax-related.

The U.S. Treasury has confirmed that it is preparing updated guidance in response to the policy shift, following the DOJ’s move to place qualifying cannabis products under Schedule III. The change directly affects how federal tax law applies to state-licensed medical cannabis businesses, particularly in relation to Section 280E.

Historically, 280E has prevented cannabis operators from deducting standard business expenses, significantly increasing their effective tax rates. With rescheduling, those restrictions are expected to ease for qualifying operators.

Federal officials have acknowledged that the shift could result in material improvements in after-tax income, as businesses regain access to standard deductions. At the same time, Treasury is evaluating how the changes will be implemented, including timing considerations and how compliance will be structured moving forward.

The guidance is expected to clarify how operators should approach deductions, reporting, and tax treatment under the new classification.

New Compliance Layers

The DOJ’s final order also introduces a more defined federal framework for how medical cannabis operators interact with regulators. Under the new classification, entities involved in the manufacture, distribution, or dispensing of qualifying products may be required to register with the DEA, aligning them with broader Schedule III compliance standards.

At the same time, the order makes clear that cannabis remains tightly controlled under a medical and scientific framework, consistent with international treaty obligations. Import and export activity will still require permits, and federal oversight will extend into recordkeeping, security, and reporting requirements.

Importantly, the rule also confirms that state-licensed medical operators will no longer be subject to the tax restrictions imposed by Section 280E, reinforcing expectations of improved cash flow and profitability.

What Comes Next

Despite the momentum, rescheduling remains a partial reform.

The current policy applies to medical cannabis, while adult-use markets continue to operate under a more restrictive federal framework. A formal administrative hearing process is expected to begin in June, which could shape the next phase of federal cannabis policy.

In practical terms, operators will need to reassess tax strategies, capital allocation, and compliance frameworks. Financial institutions will evaluate risk models and determine how far they can expand into the sector under evolving federal guidance.

This shift is driving more operational conversations, with forums such as Cannabis Market Spotlight: Ohio Valley focusing on how operators and investors translate policy changes into capital deployment and long-term strategy.

For now, the cannabis sector is entering a new phase, one defined less by whether reform will happen and more by how quickly the market can act on it.